France's Nanobiotix H1 net loss widens on lower revenue, absence of 2025 one-off gain

By Reuters News


Overview

  • France-based biotech firm's H1 2026 revenue declined due to prior year one-off non-cash impact

  • Net loss widened to €34.3 mln for H1 2026

  • Company raised ~€86 mln in May 2026, boosting cash to €110.9 mln and extending runway into 2029


Outlook

  • Company expects cash and cash equivalents of €110.9 mln to fund operations into 2029


Result Drivers

  • REVENUE DECLINE EXPLAINED - Co said H1 2026 revenue fell mainly due to absence of a one-off non-cash revenue item recognized in H1 2025 after transfer of NANORAY-312 study sponsorship to Johnson & Johnson

  • CLINICAL PROGRESS - Co reported promising early efficacy and safety data from JNJ-1900 (NBTXR3) studies in NSCLC and head and neck cancer

  • LOWER R&D AND SG&A EXPENSES - Co attributed reduced R&D and SG&A expenses to lower clinical activity after study sponsorship transfer and less patient recruitment


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

H1 Net Loss

EUR 34.30 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Nanobiotix SA is €52.00, about 86.1% above its September 24 closing price of €27.94


Reuters Recommended Reads

  • Sept 21 - France's Abivax H1 net loss widens on higher expenses driven by clinical programs

  • Sept 21 - AnaptysBio Q2 collaboration revenue rises on higher Jemperli royalties


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.